FindTrial
Sign In

Real-world study of Iparomlimab/Tuvonralimab-based therapy for hepatobiliary tumors

Real-world study of Iparomlimab/Tuvonralimab-based therapy for hepatobiliary tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113841
Enrollment
Unknown
Registered
2025-12-03
Start date
2025-12-05
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatobiliary tumors

Interventions

Experimental group:Iparomlimab and Tuvonralimab combined with other symptomatic treatments

Sponsors

Nantong Tumor Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Voluntary participation in this study and provision of signed informed consent; 2.Diagnosis of hepatobiliary tumors; 3.Investigator-assessed suitability for immunotherapy.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women; 2.Other malignancies besides hepatobiliary tumors; 3.Any other condition that, in the investigator's judgment, makes the subject unsuitable for study participation.

Design outcomes

Primary

MeasureTime frame
Safety;—

Secondary

MeasureTime frame
Progression-free survival;Objective Response Rate;Disease control rate;—

Countries

China

Contacts

Public ContactZhou yuan

Nantong Tumor Hospital

zhouyuan_520@163.com+86 137 7690 1058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026